Modern Lipid Management: The Updated Medicine Cabinet - Clinical Spotlight Meeting on Demand-Novel and Emerging Therapies: Bempedoic Acid

Video Transcription

Video Summary

In this video, the speaker discusses the challenges of achieving LDL cholesterol goals with statin therapy and introduces bempidoic acid as a potential non-statin therapy to fill this gap. They highlight that many patients on high-intensity statins still have elevated LDL cholesterol levels, making additional treatments necessary. The speaker explains that bempidoic acid is a prodrug that is activated in the liver, leading to LDL cholesterol reduction. It works through the same pathway as statins, but it has a different mechanism of action and may have a lower risk of musculoskeletal side effects. The speaker presents data from clinical trials showing the efficacy of bempidoic acid in reducing LDL cholesterol, especially when used in combination with ezetimibe. They also discuss potential side effects such as increased uric acid levels and tendon rupture. The speaker concludes by mentioning that ongoing outcome studies will provide more evidence about the effectiveness and safety of bempidoic acid.

Keywords

LDL cholesterol goals

bempidoic acid

non-statin therapy

musculoskeletal side effects

clinical trials